Bill Gross warns on gold momentum as regional bank stocks tumble
Director Charles W. Newhall III of Supernus Pharmaceuticals (NASDAQ:SUPN) sold 25,000 shares of common stock on October 9, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sale comes as the stock trades near its 52-week high of $51.78, having delivered an impressive 59% return over the past six months, according to InvestingPro data.
The sales were executed in two tranches, with the director disposing of 23,800 shares at a weighted average price of $50.73, for a total value of $1,207,274. These shares were sold in multiple transactions at prices ranging from $50.12 to $51.08. An additional 1,200 shares were sold at a weighted average price of $51.55, totaling $61,860. These shares were sold in multiple transactions at prices ranging from $51.39 to $51.76. The total value of shares sold amounts to $1,269,134. The timing of these sales is notable as InvestingPro analysis indicates the stock is currently in overbought territory.
Following the transactions, Newhall directly owns 104,644 shares of Supernus Pharmaceuticals, representing a stake in a company that currently maintains a market capitalization of $2.76 billion and boasts a "GREAT" financial health score according to InvestingPro’s comprehensive analysis. The sales were conducted pursuant to a 10b5-1 trading plan adopted on March 3, 2025. For deeper insights into SUPN’s valuation and growth prospects, investors can access the detailed Pro Research Report, available exclusively on InvestingPro.
In other recent news, Supernus Pharmaceuticals reported a revenue of $165 million for the second quarter of 2025, exceeding the consensus estimate of $154.3 million. However, the company’s earnings per share (EPS) were $0.40, falling short of the expected $0.48. Stifel responded to the strong revenue performance by raising its price target for Supernus to $43 from $38, while maintaining a Hold rating. Piper Sandler also adjusted its price target to $40, noting the successful launch of Onapgo, a treatment for advanced Parkinson’s disease. Piper Sandler further upgraded Supernus from Neutral to Overweight, projecting U.S. peak sales for Onapgo to exceed $300 million. Cantor Fitzgerald increased its price target to $63, citing a faster-than-expected adoption rate of Onapgo. These developments highlight the growing interest and positive outlook from analysts on Supernus Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.